NTLA - Intellia Therapeutics, Inc.

15.87
-0.700   -4.411%

Share volume: 5,468,112
Last Updated: 04-23-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$16.57
-0.70
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
40%
Profitability 25%
Dept financing 30%
Liquidity 50%
Performance 55%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
4.34%
1 Month
23.89%
3 Months
13.76%
6 Months
-38.01%
1 Year
94.01%
2 Year
-25.04%
Key data
Stock price
$15.87
P/E Ratio 
0.00
DAY RANGE
$15.56 - $16.97
EPS 
-$3.81
52 WEEK RANGE
$6.83 - $28.25
52 WEEK CHANGE
$90.97
MARKET CAP 
1.041 B
YIELD 
N/A
SHARES OUTSTANDING 
118.134 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
2.97
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,576,955
AVERAGE 30 VOLUME 
$3,262,315
Company detail
CEO: John M. Leonard
Region: US
Website: intelliatx.com
Employees: 600
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis. The firm has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells.

Recent news